Methionine Enkephalin (MENK) Inhibits tumor growth through regulating CD4+Foxp3+ Regulatory T cells (Tregs) in mice

References

• Tischler AS, DeLellis RA, Slayton VW, Blount MW, Wolfe HJ. Enkephalin-like immunoreactivity in human adrenal medullary cultures. Lab Invest 1983; 48:13-8; PMID:6337295
   PubMed Web of Science ®Google Scholar
• Piva M, Moreno JI, Jenkins FS, Smith JKA, Thomas JL, Montgomery C, Wilson CB, Sizemore RC. In vitro modulation of cytokine expression by enkephalin-derived peptides. Neuroimmunomodulation 2005; 12:339-47; PMID:16557034; http://dx.doi.org/10.1159/000091127
   PubMed Web of Science ®Google Scholar
• Hua H, Lu C, Li W, Meng J, Wang D, Plotnikoff NP, Wang E, Shan F. Comparison of stimulating effect on subpopulations of lymphocytes in human peripheral blood by methionine enkephalin with IL-2 and IFN-gamma. Hum Vaccin Immunother 2012; 8:1082-9; PMID:22854663; http://dx.doi.org/10.4161/hv.20759
   PubMed Web of Science ®Google Scholar
• McLaughlin PJ, Stack BC, Braine KM, Ruda JD, Zagon IS. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. Int J Oncol 2004; 24:227-32; PMID:14654962
   PubMed Web of Science ®Google Scholar
• Hatzoglou A, Kampa M, Castanas E. Opioid-somatostatin interactions in regulating cancer cell growth. Front Biosci 2005; 10:244-56; PMID:15574365; http://dx.doi.org/10.2741/1524
   PubMed Web of Science ®Google Scholar
• Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-duPree AE, McLaughlin PJ. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2005; 56:510-20; PMID:15947928; http://dx.doi.org/10.1007/s00280-005-1028-x
   PubMed Web of Science ®Google Scholar
• Liu J, Chen W, Meng J, Lu C, Wang E, Shan F. Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK). Cancer Immunol Immunother 2012; 61:1699-711; PMID:22392190; http://dx.doi.org/10.1007/s00262-012-1221-9
   PubMed Web of Science ®Google Scholar
• Li W, Chen W, Herberman RB, Plotnikoff NP, Youkilis G, Griffin N, Wang E, Lu C, Shan F. Immunotherapy of cancer via mediation of cytotoxic T lymphocytes by methionine enkephalin (MENK). Cancer Lett 2013
   Web of Science ®Google Scholar
• Chen W, Liu J, Meng J, Lu C, Li X, Wang E, Shan F. Macrophage polarization induced by neuropeptide methionine enkephalin (MENK) promotes tumoricidal responses. Cancer Immunol Immunother 2012; 61:1755-68; PMID:22419372; http://dx.doi.org/10.1007/s00262-012-1240-6
   PubMed Web of Science ®Google Scholar
• Wang Q, Gao X, Yuan Z, Wang Z, Meng Y, Cao Y, Plotnikoff NP, Griffin N, Shan F. Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs). Hum Vaccin Immunother 2014; 10:1836-40; PMID:25424790; http://dx.doi.org/10.4161/hv.28804
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127:759-67; PMID:20518016
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-6; PMID:12612578; http://dx.doi.org/10.1038/ni904
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61; PMID:12522256; http://dx.doi.org/10.1126/science.1079490
   PubMed Web of Science ®Google Scholar
• Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, Hamann A, Wagner H, Huehn J, Sparwasser T. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 2007; 204:57-63; PMID:17200412; http://dx.doi.org/10.1084/jem.20061852
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3(+) T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27:186-92; PMID:19064967; http://dx.doi.org/10.1200/JCO.2008.18.7229
   PubMed Web of Science ®Google Scholar
• Ge YZ, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 2012; 61:353-62; PMID:21915801; http://dx.doi.org/10.1007/s00262-011-1106-3
   PubMed Web of Science ®Google Scholar
• Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P. CD4(+)CD25(high) T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177:7398-405; PMID:17082659; http://dx.doi.org/10.4049/jimmunol.177.10.7398
   PubMed Web of Science ®Google Scholar
• Gallimore AM, Simon AK. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 2008; 27:5886-93; PMID:18836469; http://dx.doi.org/10.1038/onc.2008.269
   PubMed Web of Science ®Google Scholar
• Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, Hawkins RE. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007; 56:1743-53; PMID:17487490; http://dx.doi.org/10.1007/s00262-007-0318-z
   PubMed Web of Science ®Google Scholar
• Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174:2591-601; PMID:15728465; http://dx.doi.org/10.4049/jimmunol.174.5.2591
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Jager E, Ritter G, Old LJ, Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005; 106:1008-11; PMID:15840697; http://dx.doi.org/10.1182/blood-2005-02-0607
   PubMed Web of Science ®Google Scholar
• Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172:4676-80; PMID:15067041; http://dx.doi.org/10.4049/jimmunol.172.8.4676
   PubMed Web of Science ®Google Scholar
• Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 2007; 56:48-59; PMID:16612596; http://dx.doi.org/10.1007/s00262-006-0160-8
   PubMed Web of Science ®Google Scholar
• Sharma MD, Hou DY, Liu YJ, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH. Indoleamine 2,3-dioxygenase controls conversion of Foxp3(+) Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009; 113:6102-11; PMID:19366986; http://dx.doi.org/10.1182/blood-2008-12-195354
   PubMed Web of Science ®Google Scholar
• Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008; 9:194-202; PMID:18157133; http://dx.doi.org/10.1038/ni1549
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012; 13:e32-42; PMID:22225723; http://dx.doi.org/10.1016/S1470-2045(11)70155-3
   PubMed Web of Science ®Google Scholar
• Mailloux AW, Young MR. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J Immunol 2009; 182:2753-65; PMID:19234170; http://dx.doi.org/10.4049/jimmunol.0801124
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013; 110:17945-50; PMID:24127572; http://dx.doi.org/10.1073/pnas.1316796110
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Current Opin Immunol 2014; 27C:1-7; PMID:24413387; http://dx.doi.org/10.1016/j.coi.2013.12.005
   PubMed Web of Science ®Google Scholar
• Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F. Human FOXP3 and cancer. Oncogene 2010; 29:4121-9; PMID:20498631; http://dx.doi.org/10.1038/onc.2010.174
   PubMed Web of Science ®Google Scholar
• Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4:337-42; PMID:12612581; http://dx.doi.org/10.1038/ni909
   PubMed Web of Science ®Google Scholar
• Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4(+) CD25(+) regulatory cells. J Immunol 2006; 176:3321-9; PMID:16517699; http://dx.doi.org/10.4049/jimmunol.176.6.3321
   PubMed Web of Science ®Google Scholar
• Kong KF, Fu G, Zhang Y, Yokosuka T, Casas J, Canonigo-Balancio AJ, Becart S, Kim G, Yates JR 3rd, Kronenberg M, et al. Protein kinase C-eta controls CTLA-4-mediated regulatory T cell function. Nat Immunol 2014; 15:465-72; PMID:24705298; http://dx.doi.org/10.1038/ni.2866
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3:135-42; PMID:11812990; http://dx.doi.org/10.1038/ni759
   PubMed Web of Science ®Google Scholar
• Esplugues E, Sancho D, Vega-Ramos J, Martinez C, Syrbe U, Hamann A, Engel P, Sánchez-Madrid F, Lauzurica P. Enhanced antitumor immunity in mice deficient in CD69. J Exp Med 2003; 197:1093-106; PMID:12732655; http://dx.doi.org/10.1084/jem.20021337
   PubMed Web of Science ®Google Scholar
• Sancho D, Gomez M, Viedma F, Esplugues E, Gordon-Alonso M, Garcia-Lopez MA, de la Fuente H, Martínez-A C, Lauzurica P, Sánchez-Madrid F. CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis. J Clin Invest 2003; 112:872-82; PMID:12975472; http://dx.doi.org/10.1172/JCI200319112
   PubMed Web of Science ®Google Scholar
• Sharma MD, Huang L, Choi JH, Lee EJ, Wilson JM, Lemos H, Pan F, Blazar BR, Pardoll DM, Mellor AL, et al. An inherently bifunctional subset of Foxp3(+) T helper cells is controlled by the transcription factor eos. Immunity 2013; 38:998-1012; PMID:23684987; http://dx.doi.org/10.1016/j.immuni.2013.01.013
   PubMed Web of Science ®Google Scholar
• Sharma MD, Hou DY, Baban B, Koni PA, He YK, Chandler PR, Blazar BR, Mellor AL, Munn DH. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 2010; 33:942-54; PMID:21145762; http://dx.doi.org/10.1016/j.immuni.2010.11.022
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-6; PMID:12532024; http://dx.doi.org/10.1126/science.1078231
   PubMed Web of Science ®Google Scholar
• McCauley J, Zivanovic A, Skropeta D. Bioassays for anticancer activities. Methods Mol Biol 2013; 1055:191-205; PMID:23963912; http://dx.doi.org/10.1007/978-1-62703-577-4_14
   PubMedGoogle Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86; PMID:14676299; http://dx.doi.org/10.1084/jem.20030152
   PubMed Web of Science ®Google Scholar
• Haiqi H, Yong Z, Yi L. Transcriptional regulation of Foxp3 in regulatory T cells. Immunobiology 2011; 216:678-85; PMID:21122941; http://dx.doi.org/10.1016/j.imbio.2010.11.002
   PubMed Web of Science ®Google Scholar
• Choi SI, Kim BY, Dadakhujaev S, Jester JV, Ryu H, Kim TI, Kim EK. Inhibition of TGFBIp expression by lithium: implications for TGFBI-linked corneal dystrophy therapy. Invest Ophthalmol Vis Sci 2011; 52:3293-300; PMID:21310903; http://dx.doi.org/10.1167/iovs.10-6405
   PubMed Web of Science ®Google Scholar